Everolimus dose modification was permitted according to its package insert. The dual primary end points were progression-free survival according to RECIST, version 1.1, as assessed by blinded ...

For complete prescribing information, see package insert available here. The most common adverse reactions with everolimus tablets in patients treated for TSC-Associated SEGA: are stomatitis and ...

Lenvatinib in combination with pembrolizumab or everolimus has activity against advanced renal cell carcinoma. The efficacy of these regimens as compared with that of sunitinib is unclear.